Last reviewed · How we verify
SARS-CoV-2 Inactivated Vaccine
An inactivated whole-virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2 by presenting non-infectious viral particles.
An inactivated whole-virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2 by presenting non-infectious viral particles. Used for Prevention of COVID-19 caused by SARS-CoV-2.
At a glance
| Generic name | SARS-CoV-2 Inactivated Vaccine |
|---|---|
| Also known as | CoronaVac, Coronavac |
| Sponsor | PT Bio Farma |
| Drug class | Inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains chemically inactivated (killed) SARS-CoV-2 virions that cannot replicate. When administered, these viral particles trigger both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize live virus upon exposure. This approach has been used successfully in other viral vaccines such as polio and influenza.
Approved indications
- Prevention of COVID-19 caused by SARS-CoV-2
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
- Nausea
Key clinical trials
- An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older (PHASE2)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Vaccine Responses in Cancer
- Covid-19 and Influenza Oral Vaccine Study (PHASE1)
- Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-CoV-2 Inactivated Vaccine CI brief — competitive landscape report
- SARS-CoV-2 Inactivated Vaccine updates RSS · CI watch RSS
- PT Bio Farma portfolio CI